SKF 38393

Drug Profile

SKF 38393

Latest Information Update: 21 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-ischaemics; Antiparkinsonians; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Gastritis; Parkinson's disease

Most Recent Events

  • 16 Nov 1999 No-Development-Reported for Cancer in USA (unspecified route)
  • 28 Aug 1996 Preclinical development for Cancer in USA (unspecified route)
  • 13 Mar 1995 Discontinued-Unspecified phase in Gastritis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top